New hope for advanced myeloma: pfizer launches early trial
NCT ID NCT07426757
First seen Feb 28, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-phase study tests a new drug, PF-07994525, in 120 adults with advanced multiple myeloma that has returned or not responded to treatment. The goal is to find a safe dose and see if the drug can shrink tumors. Researchers will closely monitor side effects and how the body processes the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
TriStar Centennial Medical center
Nashville, Tennessee, 37203, United States
-
Tristar BMT
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.